Evidence map›Paper›PMID 37353333›Full record

ArticleRespiratory care2023

Understanding COPD Etiology, Pathophysiology, and Definition.

Jeffrey L Curtis

Open access · greenAbstract read
In one paragraph

Article in Respiratory care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jeffrey L CurtisMedical Service, VA Ann Arbor Healthcare System, Ann Arbor, Michigan; Division of Pulmonary and Critical Care Medicine, Michigan Medicine, Ann Arbor, Michigan; and Graduate Program in Immunology, University of Michigan, Ann Arbor, Michigan. jlcurtis@umich.edu.
University of Michigan · US

Funding

SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Understanding the Origins of Early COPDR01HL144718 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CURTIS, JEFFREY LOUIS, HAN, MEILAN K · 2020 to 2024
$11.3M
Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPDR01HL144849 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ARNOLD, KELLY · 2019 to 2023
$1.6M
Neutrophil Exosomes: New Pathogenic Entities in COPDI01CX001969 · VA · BIRMINGHAM VA MEDICAL CENTER · PI GAGGAR, AMIT · 2020 to 2025
–
CSRD VA I01 CX001969NHLBI NIH HHS R01 HL144718NHLBI NIH HHS R01 HL144849NHLBI NIH HHS U01 HL137880
6 · The paper itself

Abstract

COPD, one of the leading worldwide health problems, currently lacks truly disease-modifying medical therapies applicable to most patients. Developing such novel therapies has been hampered by the marked heterogeneity of phenotypes between individuals with COPD. Such heterogeneity suggests that, rather than a single cause (particularly just direct inhalation of tobacco products), development and progression of COPD likely involve both complex gene-by-environment interactions to multiple inhalational exposures and a variety of molecular pathways. However, there has been considerable recent progress toward understanding how specific pathological processes can lead to discrete COPD phenotypes, particularly that of small airways disease. Advances in imaging techniques that correlate to specific types of histological damage, and in the immunological mechanisms of lung damage in COPD, hold promise for development of personalized therapies. At the same time, there is growing recognition that the current diagnostic criteria for COPD, based solely on spirometry, exclude large numbers of individuals with very similar disease manifestations. This concise review summarizes current understanding of the etiology and pathophysiology of COPD and provides background explaining the increasing calls to expand the diagnostic criteria used to diagnose COPD and some challenges in doing so.

Indexed as

Pulmonary Disease, Chronic ObstructiveHumansLungPhenotypeSpirometryCOPDnosologypathophysiologysmall airways disease

Identifiers

PMID37353333
PMCPMC10289621
OpenAlexW4381740425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.